论文部分内容阅读
1型糖尿病是一种T细胞介导的组织特异性自身免疫性疾病,以抗胰岛细胞抗体出现、严重的胰岛炎症和自身免疫性胰岛β细胞破坏为特征。间充质干细胞(mesenchymal stem cells,MSCs)是一类具有自我更新,多向分化潜能,免疫调节和低免疫原性的细胞。近年来越来越多的研究表明,间充质干细胞移植对1型糖尿病及其慢性并发症治疗有效。本文就间充质干细胞治疗1型糖尿病及其慢性并发症研究进展做一综述。
Type 1 diabetes is a T cell-mediated, tissue-specific autoimmune disease characterized by the presence of anti-islet cell antibodies, severe islet inflammation and autoimmune islet beta cell destruction. Mesenchymal stem cells (MSCs) are a group of cells with self-renewal, multi-directional differentiation potential, immunomodulatory and low immunogenicity. In recent years, more and more studies have shown that mesenchymal stem cell transplantation is effective in the treatment of type 1 diabetes and its chronic complications. This article reviews the progress of mesenchymal stem cells in the treatment of type 1 diabetes mellitus and its chronic complications.